▲ Peaking
Business
Endpoints News
Coverage by Endpoints News as tracked by Newsylist.
130trends covered
38broke first
131articles tracked
▲ Peaking
Business
🔮 holds
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
▲ Peaking
Business
🔮 holds ✗
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
↑ Rising
Business
🔮 holds ✗
Servier’s $1.5B bet on Edgewise drug fails five months in
↓ Cooling
Business
🔮 holds ✗
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
◼ Archived
Business
🔮 holds ✗
AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
◼ Archived
Business
🔮 holds ✗
Treasury's COINS rule draft would narrow the path for China biotech dealmaking, experts say
◼ Archived
Business
🔮 fades ✓
Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster
◼ Archived
Business
🔮 holds ✗
Ferring Signs $1.4 Billion Deal to Buy Gameto Fertility Startup
◼ Archived
World
🔮 holds ✗
Roche’s changing plans show how MFN is complicating European drug launches
◼ Archived
Business
🔮 fades ✓
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
◼ Archived
Business
🔮 holds ✗
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
◼ Archived
Business
🔮 holds ✗
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
◼ Archived
Business
🔮 holds ✗
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
◼ Archived
Business
🔮 holds ✗
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
◼ Archived
Business
🔮 fades ✓
Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
◼ Archived
Health
🔮 holds ✗
Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
◼ Archived
Business
🔮 holds ✗
Treasury expected to be harder on China biotech deals in new rules
◼ Archived
Business
🔮 holds ✗
What to expect from the Moderna-Merck cancer vaccine data reveal
◼ Archived
Business
🔮 holds ✗
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
◼ Archived
Business
🔮 holds ✗
Roche returns to China’s Hansoh for $15B biobucks ADC pact
◼ Archived
Business
🔮 holds ✗
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
◼ Archived
Business
🔮 holds ✗
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
◼ Archived
Business
🔮 fades ✓
FDA’s New Leadership Aims to Overhaul Rare Disease Approvals
◼ Archived
Business
🔮 holds ✗
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
◼ Archived
Business
🔮 holds ✗
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
◼ Archived
Business
🔮 fades ✓
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
◼ Archived
Health
🔮 holds ✗
Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma
◼ Archived
Business
🔮 fades ✓
Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months
◼ Archived
Business
🔮 fades ✓
US government, Google join Zuckerberg-backed Biohub in $1.8 billion push for AI biology data
◼ Archived
Health
🔮 fades ✓
Experimental vaccine shows promise against deadly brain cancer in some patients
◼ Archived
Business
🔮 fades ✓
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
◼ Archived
Business
🔮 holds ✗
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
◼ Archived
Business
🔮 holds ✗
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
◼ Archived
Business
🔮 holds ✗
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
◼ Archived
Business
🔮 holds ✗
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
◼ Archived
Business
🔮 holds ✗
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
◼ Archived
World
🔮 fades ✓
Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
◼ Archived
Business
🔮 holds ✗
Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech
◼ Archived
Business
🔮 holds ✗
Pharma's new top lobbyist is former Majority Leader Eric Cantor
◼ Archived
Business
🔮 holds ✗
Oura becomes latest US IPO hopeful to delay listing as market jitters deepen
◼ Archived
Business
🔮 holds ✗
Merck licenses a KRAS G12D inhibitor for $400M upfront
◼ Archived
Business
🔮 fades ✓
Roche Halts Development of Obesity Drug Candidate
◼ Archived
Business
🔮 holds ✗
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
◼ Archived
Business
🔮 holds ✗
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
◼ Archived
Business
🔮 holds ✗
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
◼ Archived
Business
🔮 holds ✗
Merck sees pivotal victory for $3B eye disease prospect
◼ Archived
Business
🔮 holds ✗
Basecamp raises $140M Series C, unveils six-program pipeline in test of its AI
◼ Archived
Business
🔮 holds ✗
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
◼ Archived
Business
🔮 holds ✗
Exclusive
◼ Archived
Business
🔮 holds ✗
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
◼ Archived
Business
🔮 holds ✗
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
◼ Archived
Business
🔮 holds ✗
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
◼ Archived
Business
🔮 holds ✗
Updated: Electra says $350M IPO will help it become a commercial biotech
◼ Archived
Business
🔮 holds ✗
FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
◼ Archived
Business
🔮 holds ✗
Novartis’ TREM2 drug fails Phase 2 ALS trial
◼ Archived
Business
🔮 fades ✓
Ozempic-maker turns to Anthropic to turbocharge medical research
◼ Archived
Business
🔮 holds ✗
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
◼ Archived
Business
🔮 holds ✗
FDA names acting heads of drug and vaccine centers to permanent roles
◼ Archived
Health
🔮 fades ✓